Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals — Q3 2025 Earnings Presentation

35 slides from Day One Biopharmaceuticals's earnings presentation, Nov 4, 2025

  1. Slide 1: Targeted therapies for people of all ages

    Targeted therapies for people of all ages November 2025 Day One Biopharmaceuticals

  2. Slide 2: Disclaimer

    Disclaimer This presentation and the accompanying oral commentary contain forward-looking statements that are based on our management’s beliefs and assumptions and on information currently available to our management. Forward-looking statements are inherently subject to risks and uncertainties, some

  3. Slide 3: Developing new medicines for people of all ages with life-threatening diseases

    Inspired by the urgent needs of children, Day One creatively and intentionally develops new medicines for people of all ages with life-threatening diseases

  4. Slide 4: Bringing life-changing medicines to patients sooner

    Bringing life-changing medicines to patients sooner Commercial-stage biopharmaceutical company Our goal is to develop and provide access to targeted new medicines to patients of all ages as rapidly as possible Focused on advancing first- or best-in-class medicines for childhood and adult diseases Wh

  5. Slide 5: Day One's Future Potential

    Day One’s Future Potential Value creation Continued revenue growth from OJEMDA globally Indication expansion in front-line pLGG with FIREFLY-2 Generate clinical POC data in DAY301 program Fund pipeline expansion Maintaining a strong financial foundation through thoughtful capital allocation Proven T

  6. Slide 6: Pipeline and anticipated milestones

    Product Candidate Therapeutic Area Preclinical Phase 1 Phase 2 Phase 3/ Registrational Approved Recent & Anticipated Milestones Tovorafenib Type II RAF Inhibitor OJEMDA brand name in U.S.1 Ex-U.S. Rights: 3 BRAF-altered relapsed pLGG FDA accelerated approval April 2024 EMA regulatory decision expect

  7. Slide 7: Relapsed or refractory BRAF-altered pLGG: OJEMDA

    Relapsed or refractory BRAF-altered pLGG OJEMDA Nora Living with pLGG

  8. Slide 8: A serious and life-threatening disease

    A serious and life-threatening disease *Incidence of BRAF alterations varies across pLGG subtypes. 1 Sievert AJ, Fisher MJ. Pediatric low-grade gliomas. J Child Neurol. 2009;24(11):1397-1408. doi:10.1177/0883073809342005. 2 Penman CL et al. Front Oncol. 2015;5:54. 3 Cohen AR., N Engl J Med. 2020;386

  9. Slide 9: Tablet and pediatric-friendly powder for oral suspension

    Available in tablet formulation and pediatric-friendly powder for oral suspension Overview U.S. prescribing information for OJEMDA Indication OJEMDA is indicated for the treatment of pediatric patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma harboring a BRAF

  10. Slide 10: Data from pivotal Phase 2 FIREFLY-1 trial

    Data from Pivotal Phase 2 FIREFLY-1 trial. Meaningful tumor stabilization or shrinkage may be possible with OJEMDA, in the clinical trial: 51% of children experienced tumor shrinkage by at least 25% 82% of children saw their tumors shrink or remain stable Efficacy Safety Generally well-tolerated the

  11. Slide 11: Addressable opportunity in pLGG

    1 US Census. 2 CBTRUS, Qaddoumi et al 2009, Schreck et al 2019, ClearView Analysis. 3 Penman CL et al. Front Oncol. 2015;5:54. 4 Cohen AR., N Engl J Med. 2020;386(20):1922-1931. 5 Lassaletta A, et al. J Clin Oncol. 2017;35(25):2934-2941. 6 Faulkner C, et al. J Neuropathol Exp Neurol. 2015;74(9):867-

  12. Slide 12: Delivering double-digit Q3 2025 growth across core metrics

    Delivering double-digit Q3 2025 growth across core metrics 1 Prescriptions are approximations based on data available as of September 30, 2025. Quarterly growth in net product revenue, prescriptions and new patient starts versus Q2 2025. 15% Growth in Net Product Revenue 18% $38.5M in Q3 2025 19% Gr

  13. Slide 13: Commercial execution driving strong top-line growth

    1 2024 net revenue included approximately $3.0M of revenue associated with Ex-U.S. sales which has been removed for the purposes of calculating compounded annual revenue growth rate. 2 Compounded annual growth represents the comparison of 2024 to Q3 2025 YTD U.S. net product revenue. Commercial exec

  14. Slide 14: 19% growth in new patient starts

    19% growth in new patient starts driven by 2-year follow up data3 Prescription Highlights Gaining share in the 2L setting as prescriber confidence grows High percentage of on-label patients staying on therapy month-to-month ~90% of on-label patients receiving approval on first request Accelerating u

  15. Slide 15: Positive physician experience continues to build

    Positive physician experience continues to build across treatment settings 1 Day One Biopharmaceuticals market research, self-reported data fielded September 2025 versus October 2024. Strong Persistency 2L Adoption Increasing 20 months median duration of treatment for EAP patients 75% of EAP patient

  16. Slide 16: Breadth and depth of prescribing by account

    1 Sequential growth refers to Q3 2025 versus Q2 2025. >60% of prescribing accounts have treated multiple patients with OJEMDA 28% sequential growth in number of accounts with 4 or more patients1 >80% Priority 1 accounts have initiated 4 or more patients Launch Dec 2024 Sept 2025 1 Patient 2-3 Patien

  17. Slide 17: Focused execution driving adoption; raising 2025 guidance

    Focused execution and meaningful progress driving continued adoption and treatment durability through 2025 On label patients only. Raising 2025 guidance to $145 - $150 million net product revenue OPTIMIZE PERSISTENCE Support physicians and patients to optimize their experience on OJEMDA including ef

  18. Slide 18: Strengthening the OJEMDA story with FIREFLY-1 3-year data

    We continue to strengthen the OJEMDA story through enhancing the target product profile and data generation FIREFLY-1 3-Year Data Highlighting clinical stability following treatment with OJEMDA and opportunity for retreatment Potential to further expand physician confidence and adoption while reinfo

  19. Slide 19: OJEMDA IP summary and regulatory designations

    OJEMDA IP summary and regulatory designations Composition of matter patent of tovorafenib provides protection in the U.S. out to mid-2036 (with patent term extension)1 Patent portfolio covers formulations, manufacturing methods, and uses of tovorafenib, with issued and pending applications potential

  20. Slide 20: FIREFLY-2: Pivotal Phase 3 trial in front-line pLGG

    Pivotal Phase 3 trial of tovorafenib in front-line pLGG FIREFLY-2 Bradon Living with pLGG since age 11

  21. Slide 21: FIREFLY-2 trial design and endpoints

    Trial design Endpoints Randomized, global, registrational Phase 3 trial of monotherapy tovorafenib vs SoC chemotherapy Eligibility: Patients aged up to <25 years with LGG harboring a RAF alteration and requiring first-line systemic therapy Tovorafenib available as tablets and pediatric-friendly liqu

  22. Slide 22: DAY301: PTK7-targeted antibody-drug conjugate

    PTK7-targeted antibody-drug conjugate (ADC) DAY301

  23. Slide 23: Substantial development and commercial potential for DAY301

    Substantial development and commercial potential for DAY301 Novel ADC active in preclinical models, designed to maximize therapeutic window PTK7: clinically-validated ADC target Anti-tumor activity of anti-PTK7 ADC demonstrated in Phase 1b trial of cofetuzumab pelidotin1 DAY301: potential first-in-c

  24. Slide 24: Opportunity for a next-generation PTK7 ADC

    Potential opportunity for a next-generation PTK7 ADC with improved therapeutic index Clinical results for cofetuzumab pelidotin1 demonstrated proof of concept for PTK7-targeted ADCs Cofetuzumab pelidotin activity seen in multiple tumor types: Ovarian (Pt-resistant): ORR 27% (n=63) TNBC: ORR 21% (n=2

  25. Slide 25: DAY301 designed to maximize therapeutic index

    DAY301 has been designed to maximize therapeutic index and overcome limitations of prior programs Tumor regression at tolerable doses seen in multiple preclinical models Higher HNSTD in cyno toxicology studies; payload with known safety profile High cell permeability / bystander effect; low efflux (

  26. Slide 26: Improved tumor regression for DAY301 vs benchmarks in preclinical models

    Improved tumor regression activity demonstrated for DAY301 vs. benchmarks in multiple preclinical models DAY301: First-in-class potential PDX LD1-200615 HNSCC H-score 120 Vehicle Control antibody + DAY301 payload Control antibody + auristatin payload Cofetuzumab pelidotin, 5 mg/kg DAY301, 10 mg/kg *

  27. Slide 27: PTK7 expression and patient populations by indication

    Indication PTK7 Expression (>1+) U.S. Patient Population Cases/Deaths ORR at Relapse Median OS at Relapse Endometrial 100%2 67,880/13,2503 39%7 9 months7 Esophageal SCC​ 76%1 22,370/16,1303 5%4 3 months4 Gastric 35%2 26,890/10,8803 12%14 6-14 months15 Head & Neck SCC 75%1 54,540/11,5803 32%5 7.8 mon

  28. Slide 28: DAY301 Phase 1 trial design

    Phase 1a: Monotherapy Dose Escalation FDA-cleared starting dose DL5 RD1 RD2 Identify two recommended dose levels for further evaluation, based on safety and anti-tumor activity BOIN design for efficiency of dose escalation Backfill active dose levels to generate additional safety data Enroll tumor t

  29. Slide 29: Summary

    Summary

  30. Slide 30: Third quarter 2025 financial results

    Third quarter 2025 financial results All financial information as of 9/30/25 is unaudited. 1 Includes stock-based compensation expense of $3.0 million and $10.8 million for the three and nine months ended 9/30/25, and $3.8 million and $13.2 million for the three and nine months ended 9/30/24. 2 Incl

  31. Slide 31: Well positioned for sustainable growth and long-term success

    Inserted messaging but need help with formatting. Day One is well positioned for sustainable growth and long-term success Drive OJEMDA revenue growth Execute on clinical development pipeline for FIREFLY-2 and DAY301 Leverage our development and commercialization expertise to further expand our multi

  32. Slide 32: Appendix

    Appendix

  33. Slide 33: Tovorafenib type II RAF inhibitor mechanism

    Tovorafenib is an investigational, oral, selective, CNS-penetrant, type II RAF inhibitor that was designed to inhibit both monomeric and dimeric RAF kinase Activity in tumors driven by both RAF fusions and BRAF V600E mutations Tablet and pediatric-friendly liquid suspension Once weekly dosing Curren

  34. Slide 34: Overall response rate in evaluable patients

    51% Overall response rate (RAPNO-LGG) in 76 evaluable patients Response (IRC) RAPNO-LGG n n (%) 95% CI ORR, n (%) BRAF fusion or rearrangement BRAF V600 mutation Prior MAPKi use MAPKi-naïve Median DOR, months Median TTR, months Range 76 64 12 45 31 39 39 39 (51) 33 (52) 6 (50) 22 (49) 17 (55) 13.8 5

  35. Slide 35: Warnings and Precautions; OJEMDA safety data

    Warnings and Precautions Hemorrhage Skin toxicity, including photosensitivity Hepatotoxicity Effect on growth Embryo-fetal toxicity Use in NF1- associated tumors No boxed warnings or contraindications TEAEs (≥ 30% of patients [n=137]) Preferred Term, n (%) Any Grade Grade ≥3 Any AE 137 (100) 86 (63)

Day One Biopharmaceuticals — Q3 2025 Earnings Presentation on 6ix